Lisdexamfetamine (Vyvanse) prior authorization at Cigna
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Cigna requires prior-authorization documentation for Lisdexamfetamine (Vyvanse): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
Cigna reviews Lisdexamfetamine (Vyvanse) prior authorizations against its medical policy . Cigna-specific context: Sold its Medicaid Advantage book to HCSC in 2023. Express Scripts (PBM) is Cigna-owned. Frequent class-action litigation around mental health parity.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in this class
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Cigna's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- Mental health parity violations
- Step therapy
- Specialty drug prior auth
- OON balance billing disputes
Lisdexamfetamine (Vyvanse)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- Step therapy requiring amphetamine first
- Non-formulary
- Quantity limit
Brand: Vyvanse. Generic available since 2023.
Manufacturer patient-assistance program: Takeda Help at Hand — relevant when a Cigna denial sticks and the patient needs bridge access while appealing.
How Cigna approaches Stimulants for ADHD PAs
For Lisdexamfetamine, check whether the current Cigna Stimulants for ADHD policy cites mental health parity violations. Pharmacy-benefit review for Lisdexamfetamine at Cigna is routed through Express Scripts (in-house since the 2018 acquisition). The applicable review clock depends on the member's current product, whether the request is complete and urgent, and governing plan rules. Confirm receipt and timing with Cigna; if denied, use the filing date and route printed on that denial notice. Cigna's controlled-substance overrides require prescriber attestation of DSM-5 ADHD diagnosis and a quantity rationale within the FDA-labeled daily maximum. Cigna is domiciled in CT, so unresolved appeals escalate to the CT insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead).
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://cignaforhcp.cigna.com) with the same packet plus an applicable, current clinical source supporting Lisdexamfetamine (Vyvanse)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Cigna denial on DenialHelp.
Contact Cigna
- Provider portal: https://cignaforhcp.cigna.com
Frequently asked questions
What documentation does Cigna need for Lisdexamfetamine (Vyvanse) prior auth?
Cigna's typical PA packet for Lisdexamfetamine (Vyvanse): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis.
What's the turnaround time at Cigna?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for Lisdexamfetamine (Vyvanse) at Cigna?
Preparation scenarios to check against the current notice and policy include: Mental health parity violations; Step therapy; Specialty drug prior auth. These are not measured frequency claims. For Lisdexamfetamine (Vyvanse), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
Why does Cigna impose quantity limits on Lisdexamfetamine?
Controlled-substance quantity limits at Cigna typically track DEA Schedule II daily maximum dispensing rules and the FDA-labeled maximum daily dose for the formulation. Appeal a quantity limit by attaching prescriber attestation of the calculated daily dose, the formulation rationale (IR vs ER), and the DSM-5 diagnosis documentation. Federal law does not prohibit ADHD stimulant quantity limits — these are appealed on medical-necessity grounds, not parity grounds. Pharmacy-benefit handling is routed through Express Scripts (in-house since the 2018 acquisition). External-review escalation for Cigna fully-insured policies sits with the CT insurance department.
How do I prep for a peer-to-peer with Cigna on Lisdexamfetamine (Vyvanse)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the Lisdexamfetamine (Vyvanse) PA packet
Open ApprovalHelp — generate a Lisdexamfetamine (Vyvanse) prior-auth packet tailored to Cigna's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com